Community Health Center of Branch County
Community Health Center of Branch County was paid $588K by Medicaid between May 2019 and May 2024, across 46 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 37% of everything it billed.
COLDWATER, MI 49036
Next to other Clinical Medical Laboratory providers in Michigan
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 2,602 | $27K | |
| 2020 | 6,270 | $136K | |
| 2021 | 8,593 | $191K | |
| 2022 | 9,201 | $104K | |
| 2023 | 10,831 | $98K | |
| 2024incomplete | 3,701 | $32K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 37% | 3,367 | 3,276 | $216K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 9.2% | 2,274 | 2,222 | $54K |
| 80053 | Comprehensive metabolic panel | 6.4% | 4,915 | 4,717 | $38K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 5.4% | 1,653 | 1,601 | $32K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 5.4% | 1,433 | 1,422 | $32K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 5.4% | 1,429 | 1,418 | $32K |
| 84443 | Thyroid stimulating hormone (TSH) | 4.8% | 2,456 | 2,428 | $28K |
| 80061 | Lipid panel | 4.7% | 2,901 | 2,888 | $28K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 4.4% | 1,290 | 1,282 | $26K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.0% | 4,452 | 4,123 | $24K |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.4% | 2,147 | 2,122 | $14K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 2.1% | 695 | 695 | $12K |
34 more codes
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.1% | 1,227 | $6K |
| 84439 | <1% | 843 | $5K | |
| 82607 | <1% | 439 | $5K | |
| 85027 | <1% | 984 | $5K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 96 | $4K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 164 | $4K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 204 | $3K |
| 82570 | <1% | 895 | $3K | |
| 82043 | <1% | 723 | $3K | |
| 86780 | <1% | 228 | $2K | |
| 86803 | <1% | 195 | $2K | |
| 82728 | <1% | 164 | $2K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 13 | $1K |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,747 | $1K |
| 83540 | <1% | 228 | $1K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 174 | $950.04 |
| 87340 | <1% | 129 | $864.52 | |
| 83550 | <1% | 136 | $811.63 | |
| 87510 | <1% | 43 | $566.26 | |
| 87480 | <1% | 43 | $566.26 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 12 | $500.87 |
| 87660 | <1% | 43 | $486.10 | |
| 87077 | <1% | 65 | $389.64 | |
| 86762 | <1% | 39 | $339.89 | |
| 87807 | <1% | 40 | $328.69 | |
| 87150 | <1% | 12 | $307.86 | |
| 86140 | <1% | 87 | $296.75 | |
| 86850 | <1% | 40 | $232.33 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 13 | $143.33 |
| 81001 | <1% | 42 | $90.85 | |
| 82950 | <1% | 26 | $90.26 | |
| 86901 | <1% | 40 | $68.40 | |
| 86900 | <1% | 40 | $68.40 | |
| 87081 | <1% | 12 | $58.20 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.